IMCR Stock Analysis: Buy, Sell, or Hold?
IMCR - Immunocore Holdings plc American Depositary Shares
$29.29
-0.15 (-0.51%)
▼
5d:
-3.49%
30d:
-9.32%
90d:
-18.93%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When IMCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMCR is currently trading at $29.29, which is considered oversold relative to its 30-day fair value range of $30.22 to $32.99.
Technical Outlook: Technically, IMCR is in a strong downtrend. The price is currently testing key support at $28.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IMCR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $63.86 (+118.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMCR is in a strong downtrend. The price is currently testing key support at $28.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IMCR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $63.86 (+118.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$30.22 -
$32.99
Company Quality Score
47/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 118.0% below Wall St target ($63.86)
Fair Price Analysis
30-Day Fair Range
$30.22 -
$32.99
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.13
(7.3%)
Support & Resistance Levels
Support Level
$28.90
Resistance Level
$31.65
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.20
Wall Street Target
$63.86
(+118.0%)
Revenue Growth (YoY)
24.3%
Earnings Growth (YoY)
822.0%
Profit Margin
-8.9%
Share & Embed Analysis
Last updated: March 30, 2026 10:49 PM ET
Data refreshes hourly during market hours. Next update: 11:49 PM
Data refreshes hourly during market hours. Next update: 11:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Bahija Jallal
SELL
11474 shares
2026-02-18
David M Berman
SELL
5965 shares
2026-02-18
John Goll
SELL
698 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 56 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 45 HOLD |
